Tirzepatide is a dual GLP-1/GIP receptor agonist used for weight management and type 2 diabetes.
Tirzepatide activates two gut-hormone receptors (GLP-1 and GIP), which together reduce appetite and improve how the body handles blood sugar. It is the active ingredient in brand products Mounjaro and Zepbound and is also offered in compounded form by some clinics. Like semaglutide, it is given as a weekly injection and titrated up gradually under medical supervision.
FDA-approved tirzepatide indicated for chronic weight management.
Pharmacy-compounded tirzepatide offered as a lower-cost option by some clinics.
Once-weekly self-administered subcutaneous injection with clinic follow-up.
Virtual evaluation with shipped medication and remote check-ins.
A Florida medical license lets a physician practice, but board certification is the signal that a doctor completed accredited residency training and passed rigorous exams in their specialty. Look for certification by the American Board of Medical Specialties (ABMS) member board that matches the care you need — and verify it yourself.
Procedure facts on this page draw on authoritative medical sources. Confirm specifics in a consultation.
Obesity Medicine Association ↗NIH — National Institute of Diabetes & Digestive & Kidney Diseases ↗Choose a board-certified doctor — and verify it yourself:
ABMS — Certification Matters ↗ Look up any U.S. physician’s board certification across all 24 ABMS member specialty boards. Florida DOH — License Verification ↗ Confirm an active Florida license and review any disciplinary history. NPI Registry (CMS) ↗ Verify a provider’s national identifier and registered specialty taxonomy. Medicare Care Compare ↗ Compare clinicians, hospitals and facilities on quality measures.